Last reviewed · How we verify
NCT04004637
CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia
Phase 1 trial testing CD7 CAR-T cells infusion in T-lymphoblastic Lymphoma in 10 participants. Status unknown.
1 June 2021
Quick facts
| Lead sponsor | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 25 August 2019 |
| Primary completion | 1 June 2021 |
| Estimated completion | 1 June 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- CD7 CAR-T cells infusion — full drug profile →
Conditions studied
- T-lymphoblastic Lymphoma — all drugs for T-lymphoblastic Lymphoma →
- NK/T Cell Lymphoma — all drugs for NK/T Cell Lymphoma →
- Acute Lymphocytic Leukemia — all drugs for Acute Lymphocytic Leukemia →
Sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd. — full company profile →
Who can join
Adults 7 to 70, any sex, with T-lymphoblastic Lymphoma or NK/T Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed to explore the safety and efficacy of CD7 CAR-T Cells for patients with relapse/refractory CD7+ NK/T cell lymphoma ,T-lymphoblastic lymphoma and Acute Lymphocytic Leukemia. And to evaluate the pharmacokinetics of CD7 CAR-T cells in patients.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Recent advances in CAR-T cell engineering.
Huang R, Li X, He Y, Zhu W, et al · · 2020 · cited 274× · PMID 32616000 · DOI 10.1186/s13045-020-00910-5 -
Nanobody-based CAR-T cells for cancer immunotherapy.
Safarzadeh Kozani P, Naseri A, Mirarefin SMJ, Salem F, et al · · 2022 · cited 119× · PMID 35468841 · DOI 10.1186/s40364-022-00371-7 -
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.
Tang L, Huang Z, Mei H, Hu Y. · · 2023 · cited 98× · PMID 37591844 · DOI 10.1038/s41392-023-01521-5 -
The contemporary management of cancers of the sinonasal tract in adults.
Thawani R, Kim MS, Arastu A, Feng Z, et al · · 2023 · cited 95× · PMID 35916666 · DOI 10.3322/caac.21752 -
Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions.
Fleischer LC, Spencer HT, Raikar SS. · · 2019 · cited 95× · PMID 31884955 · DOI 10.1186/s13045-019-0801-y -
KIR Receptors as Key Regulators of NK Cells Activity in Health and Disease.
Dębska-Zielkowska J, Moszkowska G, Zieliński M, Zielińska H, et al · · 2021 · cited 84× · PMID 34359951 · DOI 10.3390/cells10071777 -
Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years.
Alexander E, Leong KW. · · 2024 · cited 83× · PMID 39455963 · DOI 10.1186/s12951-024-02900-y -
Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma.
Zhang M, Chen D, Fu X, Meng H, et al · · 2022 · cited 82× · PMID 35435984 · DOI 10.1158/1078-0432.ccr-21-4097
Verify or expand the search:
- PubMed search for NCT04004637
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CD7 CAR-T cells infusion
Trials testing the same drug.
- NCT06925464 — CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas · Phase 1, PHASE2 · recruiting
- NCT07139600 — Multi-omics Profiling of Patients With Aplastic Anemia Before and After CD7-CAR-T Therapy · active not recruiting
Other recruiting trials for T-lymphoblastic Lymphoma
Currently open trials in the same condition.
- NCT07523555 — Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies · Phase 1, PHASE2 · recruiting
- NCT06633341 — Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma · EARLY_PHASE1 · recruiting
- NCT06376721 — Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma · Phase 1, PHASE2 · recruiting
- NCT06136364 — CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study · Phase 1 · recruiting
Other PersonGen BioTherapeutics (Suzhou) Co., Ltd. trials
Trials by the same sponsor.
- NCT07338604 — Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies · EARLY_PHASE1 · recruiting
- NCT07284927 — Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies · Phase 1 · recruiting
- NCT07312630 — Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malign · EARLY_PHASE1 · recruiting
- NCT07188610 — PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma · Phase 2 · recruiting
- NCT06970951 — Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04004637 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- Last refreshed: 28 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04004637.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing